How to use semaglutide tablets for weight loss: the practical guide

What the MHRA approval tells us about how Wegovy tablets must be taken

The June 2026 MHRA approval of Wegovy tablets (the UK was the first country in Europe to authorise an oral GLP-1 for weight management) came with a specific set of instructions baked into the medicine's design. Semaglutide is a large molecule that the gut normally breaks down before it can be absorbed. The tablet co-formulates semaglutide with an absorption enhancer called SNAC, which briefly raises the local pH in the stomach lining to allow the drug through. That chemistry only works under precise conditions.

You take the tablet first thing in the morning, before anything else. Use plain water only, up to around 120 ml, a small glassful. Then wait at least 30 minutes before eating, drinking anything other than water, or taking any other oral medicines. The NHS semaglutide medicines page reinforces this: a quick check of that page takes under a minute and confirms the exact timing guidance your prescriber will also give you. Swallow the tablet whole; do not crush, split or chew it.

Missing that 30-minute window on even a handful of mornings across a treatment cycle can meaningfully reduce how much semaglutide you absorb, which feeds directly into the gap between the average trial result and what fully adherent participants achieved. That is not a reason for alarm, it is a reason to treat the morning routine as genuinely important rather than approximate. If you want to understand exactly what is required each morning, our step-by-step guide to how to take semaglutide tablets covers the fasting rule and common pitfalls in detail, including the mistakes that most often catch people out.

The dose ladder: why starting at 1.5 mg is deliberate, not cautious

Wegovy tablets follow a four-rung schedule: 1.5 mg, then 4 mg, then 9 mg, then 25 mg. The minimum time at each level is one month, and your prescriber sets when you move up based on your tolerability and response. The starting dose exists to settle your digestive system rather than to produce immediate weight-loss effects, gastrointestinal side effects such as nausea, loose stools and indigestion were reported in about 74% of tablet users in the OASIS 4 trial (versus 42% on placebo), and they are considerably more manageable when the body has time to adapt at each level.

Patients already established on the 2.4 mg weekly injection form of Wegovy may, subject to clinical assessment, move directly to the 25 mg tablet rather than restarting from 1.5 mg. That is a clinical decision, not a self-directed one. If you are considering switching between the two, our detailed comparison of semaglutide tablets versus the injection covers the practical differences between the two formats, including how efficacy, convenience and dosing schedules compare.

A note on storage that is genuinely useful here: Wegovy tablets require no refrigeration, which removes one of the logistical friction points of the injection. Keep them in their original packaging, at room temperature, away from direct heat. Travelling with them is straightforward, no cool bag, no timing around airport security for pens. That practical difference matters for people who found the injection's cold-chain requirements awkward.

Who the tablets are licensed for, and what happens at the 25 mg maintenance dose

In the UK, Wegovy tablets are licensed for adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, raised cholesterol, obstructive sleep apnoea, or prediabetes. They are not licensed for people under 18, and they are not recommended during pregnancy, breastfeeding, or if you are trying to conceive. A prescriber assesses the full picture at consultation, including medicines you already take and any conditions that might affect suitability.

At the 25 mg maintenance dose, the trial data published at the time of MHRA approval showed around 13.6% average weight reduction over 64 weeks compared with roughly 2.4% on placebo, and approximately 17% in participants who adhered fully to the treatment regimen. That adherence difference is one of the most clinically significant pieces of information in the approval documentation: the tablet requires a consistent routine in a way the injection does not.

Rybelsus is also oral semaglutide but is licensed at different strengths (3 mg, 7 mg and 14 mg) for type 2 diabetes management, not weight loss. Those are distinct products with distinct licences. If you have seen references to oral semaglutide at those doses in a weight-loss context, our overview of semaglutide tablets explains that distinction in full, and our guide to how to take oral semaglutide sets out how the dosing and administration rules differ between Rybelsus and Wegovy tablets. Current NHS England commissioning does not include oral semaglutide for weight management; this is a private treatment route. Information on the broader landscape of licensed weight-loss treatments may help you see where it sits.

Side effects to expect, and when to get medical help

The most common side effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation, indigestion and burping. They tend to be most noticeable after starting or stepping up to the next dose level, and they generally ease within a week or two as the body adjusts. Eating smaller meals, choosing lower-fat foods, and staying well hydrated all help. None of these effects require stopping treatment unless they become severe or persistent, and that judgement belongs to your prescriber, not to a self-assessment.

Some symptoms do warrant prompt medical attention. Severe abdominal pain that spreads to your back (particularly if it comes with vomiting or does not settle) should be assessed urgently, because acute pancreatitis is a known though infrequent risk with GLP-1 medicines. The MHRA highlighted this in a Drug Safety Update published in January 2026. Signs of a serious allergic reaction (facial swelling, difficulty breathing, rapid-onset rash) also need urgent care. You can report any suspected side effect through the MHRA Yellow Card scheme, which accepts reports from patients directly.

Our clinical team's profiles are available at our clinical team page if you want to understand who reviews consultations. When you are ready to check whether Wegovy tablets are appropriate for you, speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber, with no subscription required.